Gram-negative bacterial infection randomized controlled trials (RCTs) in the 21st century: characteristics and evolution
Fabian Patauner, Hyeri Seok, Navaneeth Narayanan, Jason M Pogue, Emanuele Durante-Mangoni, Keith S Kaye · 2026
Read Gram-negative bacterial infection randomized controlled trials (RCTs) in the 21st century: characteristics and evolution by Fabian Patauner, Hyeri Seok, Navaneeth Narayanan, Jason M Pogue, Emanuele Durante-Mangoni, Keith S Kaye (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13395242.txt.
Description
Fabian Patauner and co-authors review, in 2026, trials of drugs for Gram-negative bacterial infections since 2000. These germs cause many grave hospital and community infections. The team gathered 68 trials in adults covering belly, lung, urinary, and blood infections. They read each trial's design, aims, and patient mix.
Belly and urinary infections drew the most trials. Most studies tested whether a new drug was no worse than standard care, and few aimed to prove better. New drugs featured often, yet resistant germs were rare in the patient pools. That gap weakens use of results in real wards. The authors call for more funding and rule changes to aid real-world trials.
Catalog record
| CREATOR | Fabian Patauner, Hyeri Seok, Navaneeth Narayanan, Jason M Pogue, Emanuele Durante-Mangoni, Keith S Kaye |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64192 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |